Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Clinical Research Group, Clinic for Paediatric Pneumology, Allergology and Neonatology, OE 6710, Hanover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Centre for Lung Research, Hannover, Germany. Electronic address: tuemmler.burkhard@mh-hannover.de.
Burkhard
B
Tümmler
D000627:Aminophenols / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D015363:Quinolones / Q000627:therapeutic use*; D019141:Respiratory System Agents / Q000627:therapeutic use*
D000627:Aminophenols; D015363:Quinolones; D019141:Respiratory System Agents; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor